Previous News

2018 

Kymera Therapeutics

November 13 2018 - Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing.

View PDF

 

Ovid Therapeutics 

October 25 2018 - Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting  

View PDF 

 

Ovid Therapeutics 

October 22 2018 - Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community

View PDF 

 

Unum Therapeutics 

September 17 2018 - Unum Therapeutics, today announced that the Company will be presenting data on the first dose level (40x106 ACTR+ T cells) of its ATTCK-20-03 clinical trial evaluating ACTR707 in combination with rituximab in patients with relapsed or refractory CD20-positive B cell non-Hodgkin Lymphoma (r/r NHL). 

View PDF 

 

Fulcrum Therapeutics 

September 5 2018 - Fulcrum Therapeutics, announced the closing of an $80 million Series B financing. Proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for rare, genetically based neuromuscular, central nervous system and hematologic disorders.

View PDF 

 

Evidation Health 

August 23 2018 - Evidation Health, announced today a new technology partnership with Tidepool, an open source, not-for-profit company focused on making diabetes data more accessible, actionable and meaningful for people with diabetes, their care teams and researchers.

View PDF 

 

Ovid Therapeutics 

August 16 2018 - Ovid Therapeutics announces Phase 2 STARS Topline Data Accepted for Presentation at American Academy of Child and Adolescent Psychiatry Annual Meeting

View PDF 

 

Unum Therapeutics

August 13, 2018 - Unum Therapeutics today announced that an investigational new drug (IND) application is now active for ACTR T cells in combination with Trastuzumab for the treatment of patients with HER2+ advanced cancers

View PDF 

 

Unum Therapeutics

August 13, 2018 -Unum Therapeutics today reported financial results and provided a corporate update for the second quarter ended June 30, 2018 and recent activities

View PDF 

 

Ovid Therapeutics

August 6, 2018 - Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome

View PDF 

 

Navitor Pharmaceuticals

August 2, 2018 - Navitor Pharmaceuticals Appoints Thomas E. Hughes, Ph.D. as Chief Executive Officer

View PDF 

 

Evidation Health

August 1, 2018 - Evidation Health Announces $30M in New Funding

View PDF 

 

NeuroVia

July 25, 2018 - NeuroVia Initiates Phase 1/2 Trial of NV1205 for Treating Childhood Cerebral Adrenoleukodystrophy (CCALD)

View PDF 

 

Click Therapeutics

July 23, 2018 - Sanofi Ventures Leads $17 Million Financing of Click Therapeutics

View PDF 

 

Inozyme Pharma

July 17, 2018 - Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

View PDF 

 

Ovid Therapeutics

July 11, 2018 - Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome

View PDF 

 

Sanofi Ventures

July 10, 2018 - Sanofi Doubles its Participation in Two Funds Dedicated to Innovation

View PDF 

 

Navitor Pharmaceuticals

June 26, 2018 - Navitor Pharmaceuticals Initiates a Clinical Study of NV‐5138, a Novel, Oral Small Molecule for Treatment‐Resistant Depression

View PDF 

 

Unum Therapeutics

June 25, 2018 - Unum Therapeutics Joins Russell 3000 Index

View PDF 

 

Immune Design

June 25, 2018 - Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell
Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma

View PDF 

 

Omada Health

June 20, 2018 - Omada Health Adds New Programs for Type 2 Diabetes and Hypertension Self-Management

View PDF 

 

Inozyme Pharma

June 13, 2018 - Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders

View PDF 

 

Science 37

May 31, 2018 - Sanofi Ventures Portfolio Company Science 37 is Ranked as Entrepreneur's Top 20 Companies to Watch for 2018

Link

 

Immune Design

May 24, 2018 - Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma

View PDF 

 

Unum Therapeutics

May 14, 2018 - Unum Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

View PDF 

 

Ovid Therapeutics

May 8, 2018 - Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

View PDF 

 

Immune Design

May 2, 2018 - Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update

View PDF 

 

Common Sensing

April 11, 2018 - Common Sensing Secures $6.6M Series A Investment Round to Support Injectable Medicines

View PDF 

 

Unum Therapeutics

April 3, 2018 - Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle Genetics

View PDF 

 

Immune Design

March 12, 2018 - Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma

View PDF 

 

Expansion Therapeutics

January 3, 2018 - Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases  

View PDF 

 

2017 

Ovid Therapeutics

December 20, 2017 - Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome

View PDF 

 

Ovid Therapeutics

December 19, 2017 - Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

View PDF 

 

Curisium

December 14, 2017 - Curisium Raises $3.5M to Scale Innovative Healthcare Contracting on Blockchain

View PDF 

 

Ovid Therapeutics

December 5, 2017 - Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

View PDF 

 

Ovid Therapeutics

December 3, 2017 - Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

View PDF 

 

Ovid Therapeutics

November 28, 2017 - Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents

View PDF 

 

Inozyme Pharma

November 15, 2017 - Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone

View PDF 

 

Immune Design

October 19, 2017 - Immune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s Lymphoma

View PDF 

 

Ovid Therapeutics

October 16, 2017 - Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model

View PDF 

 

Immune Design

October 16, 2017 - Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients

View PDF 

 

Ovid Therapeutics

October 5, 2017 - Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop

View PDF 

  

Immune Design

September 8, 2017 - New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response

View PDF 

 

Ovid Therapeutics

September 6, 2017 - Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel

View PDF 

 

Immune Design

August 30, 2017 - Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress

View PDF 

 

Ovid Therapeutics

August 21, 2017 - Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies

View PDF 

 

Ovid Therapeutics

August 10, 2017 - Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress

View PDF 

 

Evidation Health

July 31, 2017 - Sanofi Strengthens Ties with Evidation Health, Leader in Quantifying Health Behaviors

View PDF 

 

NeuroVia

July 20, 2017 - NeuroVia Closes Series A Financing Round of $14M to Develop Novel Treatment Option for X-ALD Disease

View PDF 

 

Ovid Therapeutics

June 23, 2017 - Ovid Therapeutics to be Added to Russell 2000®, 3000® and Microcap® Indexes

View PDF 

 

Omada Health

June 14, 2017 - Omada Health Raises $50 Million, Led by Cigna

View PDF 

 

Ovid Therapeutics

June 13, 2017 - Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress

View PDF 

 

Immune Design

May 17, 2017 - Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update

View PDF 

 

Immune Design

May 17, 2017 - New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms

View PDF 

 

Evidation Health

April 27, 2017 - Evidation Health secures Financing from Sanofi-Genzyme BioVentures to Fuel Commercial Growth

View PDF 

 

Science 37

April 25, 2017 - Science 37 Raises $29M To Bring Clinical Trials Directly Into Patients' Homes

View PDF

 

Ovid Therapeutics

April 10, 2017 - Ovid Therapeutics Announces Initiation of Phase 1 Clinical Trial of OV101 for Adolescents with Angelman Syndrome or Fragile X Syndrome

View PDF

 

GlycoMimetrics

March 7, 2017 - GlycoMimetrics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271

View PDF

 

Science 37

March 1, 2017 - Science 37 and Sanofi Introduce a New Partnership

View PDF

 

Immune Design

March 7, 2017 - Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update.

View PDF

 

Immune Design

March 1, 2017 - Immune Design To Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at AACR Annual Meeting 2017.

View PDF

 

Immune Design

February 22, 2017 - Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate

View PDF

 

Ovid Therapeutics

February 9, 2017 - Ovid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome

View PDF

 

Ovid Therapeutics

February 9, 2017 - Ovid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman

View PDF

 

Ovid Therapeutics

January 19, 2017 - Ovid Therapeutics Names Jacqueline A. French, M.D. to Scientific Advisory Board

View PDF

 

Ovid Therapeutics

January 18, 2017 - Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies

View PDF

 

Lysosomal Therapeutics

January 9, 2017 - Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-in-Class Breakthrough Compounds

View PDF

 

2016 

Immune Design

December 5, 2016 - Immune Design Provides Update from Two Discovery Platforms:  DC-tropic ZVex and G100

View PDF

 

Immune Design

November 11, 2016 - Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update

View PDF

 

Science 37

October 18, 2016 - Science 37 Secures $31M Series B Funding to Expand Clinical Trial Access to Anyone, Anywhere, Anytime

View PDF

 

Immune Design

September 28, 2016 -Immune Design Announces Advancement of First GLAAS™-based Allergy Program into Clinical Development

  View PDF

 

Ovid Therapeutics

September 8, 2016 - Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for the Treatment of Patients with Angelman Syndrome

  View PDF

 

Yumanity Therapeutics

June 22, 2016 - Yumanity Therapeutics and the New York Stem Cell Foundation Research Institute Announce Discovery Collaboration

   View PDF

 

Immune Design

June 8, 2016 - Immune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates

 View PDF

 

Immune Design

May 10, 2016 - Immune Design Reports First Quarter 2016 Financial Results and Provides Corporate Update

 View PDF

 

Immune Design

May 9, 2016 - Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy.

 View PDF

 

Immune Design

April 20, 2016 - Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches

 View PDF

 

ImmuneXcite

March 30, 2016 - ImmuneXcite Closes $8.6M Financing, Adds Three Industry Veterans to Company Leadership

 View PDF

 

Immune Design

March 10, 2016 - Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

 View PDF

 

Immune Design

March 4, 2016 - Immune Design's GLAAS™ Platform Shown to Modulate the Allergic Immune Response

 View PDF

 

Proteostasis Therapeutics

February 11, 2016 - Proteostasis Therapeutics, Inc. Announces Pricing of Initial Public Offering

View PDF

 

Yumanity Therapeutics

February 10, 2016 - Yumanity Therapeutics Closes $45 Million Series A Financing

View PDF

 

Immune Design

February 9, 2016 - Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates

View PDF

 

Proteostasis Therapeutics

February 1, 2016 - Proteostasis Therapeutics Receives FDA Fast Track Designation for PTI-428 in Patients with Cystic Fibrosis

View PDF

 

Unum Therapeutics

January 26, 2016 - Unum Therapeutics Moves to New Headquarters in Cambridge, MA as it continues to Expand and Advance its Cellular Immunotherapy Pipeline

View PDF

 

Immune Design

January 8, 2016 - Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305

View PDF

 

2015 

Navitor Pharmaceuticals 

December 18, 2015 - Navitor Pharmaceuticals Announces $33M Series B Financing

View PDF 

 

Proteostasis Therapeutics

December 11, 2015 - Proteostasis Therapeutics Inc. announces management changes to strengthen Research and Development Organization

View PDF 

 

Immune Design

December 7, 2015 - Immune Design Highlights G100 Preclinical Data Demonstrating Direct and Abscopal Tumor Regression, Long-Term Response and Synergy With Checkpoint Blockade

View PDF 

 

Ovid Therapeutics

November 23, 2015 - Ovid Therapeutics Announces Election of Bart Friedman to Its Board of Directors

View PDF 

 

Proteostasis Therapeutics

November 20, 2015 - Proteostasis Therapeutics, Inc. Demonstrates Therapeutic Potential of a Proprietary Triple Combination Therapy for the Treatment of Cystic Fibrosis that Restores Activity of Mutant F508del CFTR protein to 80% of Normal

View PDF 

 

Immune Design

November 12, 2015 - Immune Design Reports Third Quarter 2015 Financial Results

View PDF 

 

Immune Design

November 11, 2015 - Immune Design Announces Start of Ramdomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma

View PDF 

 

Immune Design

November 3, 2015 - Immune Design Presents Preclinical Data on G100 and ZVex(TM) in Combination With Check Point Inhibitors at the 2015 Society for Immunotherapy of Cancer Annual Meeting
View PDF 

 

Immune Design

October 29, 2015 - MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS(TM) Discovery Platform
View PDF 

 

Unum Therapeutics

October 21, 2015 - Unum Therapeutics Expands Leadership Team by Appointing Dr. Michael J. Vasconcelles as Chief Medical Officer
View PDF 

 

Proteostasis Therapeutics

October 8, 2015 - Proteostasis Therapeutics, Inc. Presents Preclinical Data for Its CFTR Amplifier Program at the 29th Annual North American Cystic Fibrosis Conference
View PDF 

 

Ovid Therapeutics

October 8, 2015 - Ovid Therapeutics Appoints Dr. Jerome B. Zeldis to Its Scientific Advisory Board
View PDF 

 

Unum Therapeutics

September 30, 2015 - Unum Therapeutics selected as a Fierce 15 company
View PDF 

 

Ovid Therapeutics 

September 30, 2015 - Ovid Therapeutics Appoints Dr. Karen Bernstein to its Board of Directors
View PDF 

 

Proteostasis Therapeutics

September 8, 2015 - Proteostasis Therapeutics, Inc. Raises $37 Million in Crossover Financing
View PDF 

 

Selecta Biosciences

September 8, 2015 - Selecta Announces $38 Million Series E Equity Financing 
View PDF 

 

Immune Design

August 12, 2015 - Immune Design Reports Second Quarter 2015 Financial Results 
View PDF 

 

Immune Design

August 12, 2015 - Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration 
View PDF 

 

Ovid Therapeutics

August 11, 2015 - Ovid Therapeutics Completes Oversubscribed $75 Million Series B Financing 
View PDF 

 

Immune Design

August 10, 2015 - Immune Design and Merk to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-Hodgkin's Lymphoma and Melanoma 
View PDF 

 

Fate Therapeutics

August 5, 2015 - Fate Therapeutics Reports Second Quarter 2015 Financial Results 
View PDF 

 

KaloBios

July 29, 2015 - KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 
View PDF 

 

GlycoMimetics

June 23, 2015 - GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel 
View PDF 

 

Unum Therapeutics

June 11, 2015 - Unum Therapeutics Announces $65 Million Series B Financing Round 
View PDF 

 

Unum Therapeutics

June 8, 2015 - Seattle Genetics and Unum Therapeutics Enters Into Strategic Cancer Immunotherapy Collaboration 
View PDF 

 

Fate Therapeutics

June 5, 2015 - Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases
View PDF 

 

Fate Therapeutics

May 20, 2015 - Fate Therapeutics Announces Pricing of Public Offering of Common Stock
View PDF 

 

Fate Therapeutics

May 18, 2015 - Fate Therapeutics Announces Proposed Public Offering of Common Stock
View PDF 

 

Immune Design

May 14, 2015 - Immune Design Reports First Quarter Financial Results
View PDF 

 

Immune Design

May 13, 2015 - Immune Design Announces Positive Data from Three Phase 1 Studies at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
View PDF 

 

Fate Therapeutics

May 7, 2015 - Fate Therapeutics Reports First Quarter 2015 Financial Results
View PDF 

 

Fate Therapeutics

May 6, 2015 - Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies
View PDF 

 

Immune Design

April 15, 2015 - Immune Design Prices Public Offering of Common Stock
View PDF 

 

Immune Design

March 31, 2015 - Immune Design Announces Postivie Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents
View PDF 

 

Immune Design

March 31, 2015 - Immune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
View PDF 

 

Immune Design

March 26, 2015 - Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent
View PDF 

 

Fate Therapeutics

March 12, 2015 - Fate Therapeutics Reports Year-End 2014 Financial Results
View PDF 

 

Fate Therapeutics

March 3, 2015 - Fate Therapeutics Expands and Strengthens Leadership Team
View PDF 

 

Immune Design

February 11, 2015 - Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100 Investigational Immuno-Oncology Agent
View PDF 

 

Proteostasis Therapeutics

February 4, 2015 - Proteostasis Therapeutics Announces a New Class of Agents for Cystic Fibrosis Called CFTR Amplifiers and Selects PTI130 as a Development Candidate
View PDF 

 

Lysosomal Therapeutics

February 3, 2015 - Lysosomal Therapeutics Inc. Raises $20 Million in Series A Financing
View PDF 

 

Ultragenyx Pharmaceutical

January 12, 2015 - Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
View PDF 

 

Fate Therapeutics

January 12, 2015 - Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline
View PDF 

 

Ultragenyx Pharmaceutical

January 7, 2015 - Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin
View PDF 

 

2014

Fate Therapeutics

December 18, 2014 - Fate Therapeutics Announces Iterim Data From Ongoing Phase 2 PUMA Study
View PDF 

 

Ultragenyx Pharmaceutical

December 15, 2014 - Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
View PDF 

 

Proteostasis Therapeutics

December 3, 2014 - Proteostasis Therapeutics Announces Appointment of Dr. Po-Shun Lee as Vice President of Clinical Development
View PDF 

 

Immune Design

November 12, 2014 - Immune Design Reports Third Quarter 2014 Financial Results and Provides Corporate Update
View PDF 

 

Fate Therapeutics

November 11, 2014 - Fate Therapeutics Reports Third Quarter 2014 Financial Results
View PDF 

 

Ultragenyx Pharmaceutical

November 10, 2014 - Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update
View PDF 

 

Proteostasis Therapeutics

November 6, 2014 - Proteostasis Therapeutics Announces Scientific Publication in Cell Reports
View PDF 

 

Proteostasis Therapeutics

November 4, 2014 - Proteostasis Therapeutics and Astellas Announce Collaboration for Research, Development and Commercialization of Therapies Modulating the Unfolded Protein Response
View PDF 

 

Unum Therapeutics

October 21, 2014 - Fidelity Biosciences and Atlas Venture Lead $12 Million Series A Funding to Launch Unum Therapeutics, a New Cellular Immunotherapy Company
View PDF 

 

Proteostasis Therapeutics

October 20, 2014 - Proteostasis Therapeutics Announces Appointments of Cystic Fibrosis Experts to Inaugural Clinical Advisory Board
View PDF 

 

Immune Design

October 16, 2014 - Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
View PDF 

 

Ultragenyx Pharmaceutical

October 13, 2014 - Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
View PDF 

 

Immune Design

October 2, 2014 - Immune Design Added to Russell 2000(R) Index
View PDF 

 

Ultragenyx Pharmaceutical

September 15, 2014 - Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients with X-Linked Hypophosphatemia
View PDF 

 

Ultragenyx Pharmaceutical

September 3, 2014 - Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucruronidase in Mucopolysaccharidosis 7
View PDF 

 

KaloBios

August 14, 2014 - Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
View PDF 

 

Fate Therapeutics

August 12, 2014 - Fate Therapeutics Reports Second Quarter 2014 Financial Results
View PDF 

 

Ultragenyx Pharmaceutical

August 11, 2014 - Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update
View PDF 

 

Immune Design

August 7, 2014 - Sanofi Licenses Immune Design's GLAAS Platform to Explore Novel Approach to Treat Food Allergy
View PDF 

 

Ultragenyx Pharmaceutical

August 5, 2014 - Ultragenyx Announces License of Intellectual Property for the Treatment of Epilepsy and Other Seizure-Related Disorders With Triheptanoin
View PDF 

 

Fate Therapeutics

July 31, 2014 - Fate Therapeutics Secures Up to $20 Million in Debt Financing
View PDF 

 

Proteostasis Therapeutics

July 30, 2014 - Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
View PDF 

 

Fate Therapeutics

July 29, 2014 - Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders
View PDF 

 

Immune Design

July 24, 2014 - Immune Design Announces Pricing of Initial Public Offering
View PDF 

 

Ultragenyx Pharmaceutical

July 14, 2014 - Ultragenyx Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
View PDF 

 

Ultragenyx Pharmaceutical

July 9, 2014 - Ultragenyx Announces Pricing of Public Offering of Common Stock
View PDF 

 

Ultragenyx Pharmaceutical

July 1, 2014 - Ultragenyx Announces Initiation of a Phase 2 Study of KN23 for Pediatric X-Linked Hypophosphatemia in the US and EU
View PDF 

 

Fate Therapeutics

June 30, 2014 - Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders
View PDF 

 

Ultragenyx Pharmaceuticals

June 24, 2014 - Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults
View PDF 

 

Fate Therapeutics

June 5, 2014 - Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo
View PDF 

 

Immune Design

June 5, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of LV305 Immuno-Oncology Agent
View PDF 

 

Edimer Pharmaceuticals

May 28, 2014 - Edimer Pharmaceuticals' EDI200 Expands to Higher Dose Cohort in Phase 2 Trial Following Positive Review of Safety Data
View PDF 

 

Immune Design

May 27, 2014 - Immune Design's GLAAS Discovery Platform Used in MEDI7510 Phase 1 Trial for Respiratory Syncytial Virus
View PDF 

 

Fate Therapeutics

May 13, 2014 - Fate Therapeutics Reports First Quarter 2014 Financial Results
View PDF 

 

Lysosomal Therapeutics

May 12, 2014 - Lysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding
View PDF 

 

Ultragenyx Pharmaceutical

May 12, 2014 - Ultragenyx Reports First Quarter 2014 Financial Results and Corporate Update
View PDF 

 

KaloBios

May 8, 2014 - KaloBios Provides First Quarter 2014 Financial Results
View PDF 

 

Ultragenyx Pharmaceutical

April 30, 2014 - Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
View PDF 

 

Fate Therapeutics

April 23, 2014 - Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients
View PDF 

 

Fate Therapeutics

April 10, 2014 - Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics
View PDF 

 

MacroGenics

April 6, 2014 - MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity with Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting
View PDF 

 

Edimer Pharmaceuticals

April 1, 2014 - Edimer Pharmaceuticals Presents Update on Phase 2 Clinical Trial of ED1200 at International Gathering of Ectodermal Dysplasia Patient Foundations
View PDF 

 

Ultragenyx Pharmaceutical

March 27, 2014 - Ultragenyx Announces Preliminary Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
View PDF 

 

Ultragenyx Pharmaceutical

March 24, 2014 - Ultragenyx Reports Fourth Quarter and Full Year 2013 Financial Results
View PDF 

 

MacroGenics

March 20, 2014 - MacroGenics Provides Update on Corporate Progress and 2013 Financial Results
View PDF 

 

Immune Design

March 18, 2014 - Immune Design Appoints Franklin M. Berger to Board of Directors
View PDF 

 

Fate Therapeutics

March 17, 2014 - Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
View PDF 

 

KaloBios

March 13, 2014 - KaloBios Announces Fiscal Year 2013 Financial Results
View PDF 

 

Fate Therapeutics

March 12, 2014 - Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies Type-1 Deficiency Syndrome
View PDF 

 

Ultragenyx Pharmaceutical

March 11, 2014 - Ultragenyx Announces First Patient Enrolled in Phase 2 Study of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome
View PDF 

 

Immune Design

March 6, 2014 - Immune Design Appoints William Ringo to Board of Directors
View PDF 

 

Fate Therapeutics

March 6, 2014 - Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
View PDF 

 

Immune Design

February 27, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G305 Cancer Immunotherapy Agent
View PDF 

 

Fate Therapeutics

February 26, 2014 - Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R)
View PDF 

 

Ultragenyx Pharmaceutical

February 11, 2014 - Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders
View PDF 

 

KaloBios

February 11, 2014 - KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies
View PDF 

 

Ultragenyx Pharmaceutical

February 6, 2014 - Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
View PDF 

 

Ultragenyx Pharmaceutical

January 30, 2014 - Ultragenyx Announces Pricing of Initial Public Offering
View PDF 

 

Immune Design

January 27, 2014 - Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G100, an Investigational Immuno-Oncology Agent
View PDF 

 

GlycoMimetics

January 9, 2014 - GlycoMimetics Announces Pricing of Initial Public Offering
View PDF 

 

2013

Ultragenyx

December 20, 2013 - Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
View PDF 

December 4, 2013 - Ultragenyx Announces Initiation of Phase 1/2 Study of Recombinant Human Beta-Glucuronidase (rhGUS) in Mucopolysaccharidosis Type 7 (MPS 7)
View PDF 

 

Ultragenyx

December 20, 2013 - Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
View PDF 

December 4, 2013 - Ultragenyx Announces Initiation of Phase 1/2 Study of Recombinant Human Beta-Glucuronidase (rhGUS) in Mucopolysaccharidosis Type 7 (MPS 7)
View PDF 

 

bluebird bio

December 2, 2013 - bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia
View PDF 

 

Immune Design

October 30, 2013 - Immune Design Raises Up to $49 Million Series C Financing
View PDF 

 

KaloBios

October 30, 2013 - U.S. FDA Grants Orphan Drug Designation for KaloBios' KB001 - A in Treatment of Cystic Fibrosis Patients
View PDF 

 

Proteostasis Therapeutics

October 18, 2013 - Proteostasis Therapeutics Presents Promising Preclinical Data at the 27th Annual North American Cystic Fibrosis Conference
View PDF 

 

Edimer

October 8, 2013 - Edimer Initiates Phase 2 Trial of EDI200 in XLHED-Affected Male Newborns
View PDF 

 

Fate Therapeutics

October 4, 2013 - Fate Therapeutics Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
View PDF 

 

KaloBios

September 26, 2013 - KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
View PDF 

 

GlycoMimetics

September 13, 2013 - GlycoMimetics Announces EMA’s Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease
View PDF 

 

Edimer

July 30, 2013 - Edimer Secures $18M Series B Financing Led by New Enterprise Associates
View PDF 

 

bluebird bio

June 24, 2013 - bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
View PDF 

 

KaloBios

April 23, 2013 - U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa
View PDF 

 

Fate Therapeutics

April 22, 2013 - Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference
View PDF 

 

GlycoMimetics

April 16, 2013 - GlycoMimetics Announces Top Line Results from Phase 2 Trial with GMI-1070 in Sickle Cell Disease
View PDF 

 

Kahr Medical

February 4, 2013 - KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101
View PDF 

 

2012

Ultragenyx

December 19, 2012 - Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing
View PDF